Clinical Trial Update: Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating modified TOMOX-HAIC with sintilimab and a bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab biosimilar (Bevacizumab)
• Sintilimab (sintilimab)
• modified TOMOX-HAIC

Snippet

Sponsor: Fudan University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN